Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

European Leadership Changes and Appointment of VP Sales and Marketing, EMEA

News,

Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her position of Telix EU…

Read more

Telix Supports Molecular Imaging Summer Program at MSKCC

Events, News,

Telix Pharmaceuticals Ltd is pleased to announce our support of the Molecular Imaging Summer Program at…

Read more

Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American…

Read more

Robyn Jackson, MBA, CNMT Joins Telix Pharmaceuticals US

News,

With over 15 years of hands-on experience in Diagnostic Imaging and Sales, Robyn will be solidifying our presence in the Western US. Robyn has an extensive background in Diagnostic Imaging…

Read more

Anthony Zinno, MBA Joins Telix Pharmaceuticals US

News,

With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success…

Read more

NDA Clinical Briefing Package Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product…

Read more

ZIRCON Phase 3 IND Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for…

Read more

TLX101 for Brain Cancer IPAX-1 Study Update

Clinical, News,

Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma…

Read more

University of Melbourne collaboration with Telix receives Cancer Australia research grant

News,

Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research…

Read more

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

ASX, News,

Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s…

Read more
1 … 40 41 42 43 44 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings